Pharming Annual Shareholders Meeting
Leiden, The Netherlands, 11 May, 2011. Pharming Group NV (“Pharming” or “the Company”) (NYSE Euronext: PHARM) provided an update on its product, financial and corporate developments during the Annual Meeting of Shareholders (AGM) today.
During the meeting, the Company confirmed its strategy to become an international specialty pharmaceutical company. This includes the development of therapeutic products for significant medical needs, such as Ruconest/ Rhucin. With its production platform validated by the recent EU approval of Ruconest, Pharming also now intends to leverage its low cost and scalable manufacturing platform to produce other proteins.
At the AGM, the majority of the Shareholders voted in favour of the re- appointments of Dr. J.B. Ward and Mr. J. Blaak as members of the Board of Supervisory Directors of Pharming (BOSD), the re- appo intment of Dr. B. Giannetti as member of the Board of Management of Pharming (BOM), the option arrangements for the BOM, the remuneration of the BOSD, the increase in the authorised share capital by 50,000,000 shares and the re-appointment of PricewaterhouseCoopers as Auditors.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. Ruconest™ (Rhucin® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification a nd formulation of these products. Additional information is available on the Pharming website, www.pharming.com.
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact:
Karl Keegan, CFO, T: +31 (0)71 52 47 181 or +31 (0)6 3168 0465
